

## References – Pradax

- Clagett GP, Anderson FA et al. Prevention of Venous Thromboembolism. Chest 1995;108:312-334;Supplement 312S.
- Geerts WH, Pineo GF et al. Prevention of Venous Thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:338-400;supplement 338S.
- Canadian Joint Replacement Registry 2006 Report: Hip and Knee Replacements in Canada. Canadian Institute for Health Information 2006.
- Mant M, Geers B. Clinical Guide – DVT Prophylaxis in Major Orthopedic Surgery. The Thrombosis Interest Group of Canada: Clinical Guide-DVT Prophylaxis in Major Orthopedic Surgery September 2006.
- Haralson RH. Clearing up the confusion with VTE and/or PE prophylaxis guidelines. American Academy of Orthopaedic Surgeons (AAOS) 2008.
- Hull R, Raskob G et al. A comparison of subcutaneous low-molecular weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 1993;329(19):1370-1376.
- Leclerc J, Geerts W et al. Prevention of venous thromboembolism after knee arthroplasty : a randomized, double-blind trial comparing enoxaparin with warfarin. Annals of Internal Medicine 1996;124(7):619-626.
- Spiro RH et al. Enoxaparin a low molecular weight heparin and warfarin for the prevention of venous thromboembolic disease after elective knee replacement surgery. Abstract 970; N Engl J Med 1991;325:393-397.
- Lassen MR, Bauer KA et al. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery : a randomised double-blind comparison. Lancet 2002;359:1715-1720.
- Turpie A, Bauer K et al. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery : a randomised double-blind trial. Lancet 2002;359:1721-1726.
- Eriksson BI, Quinlan DJ. Oral anticoagulants in development. Drugs 2006;66:1411-29.
- Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007;370:949-56.
- Norrie J. Trials of venous thromboembolism prevention. Lancet 2007;370:915-17.
- Pechlaner C, Marschang P. Dabigatran versus enoxaparin after total hip replacement. Lancet 2007;370:2002.

Martins HS, Scalabrini-Neto A, Velasco IT. Dabigatran versus enoxaparin after total hip replacement. *Lancet* 2007;370:2002-2003.

Eriksson BI, Hantel S. Dabigatran versus enoxaparin after total hip replacement – Authors's reply. *Lancet* 2007;370:2003-2004.

Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. *J Thromb Haemost* 2007;5:2178-85.

Bauer KA. Targeted inhibition of coagulation: oral agents show promise in phase III trials. *J Thromb Haemost* 2007;5:2175-7.

Friedman RJ, Caprini JA, Comp PC, et al. Dabigatran etexilate versus enoxaparin in preventing venous thromboembolism following total knee arthroplasty. *J Thromb Haemost* 2007;5(Suppl 2):O-W-051.

<http://www.blackwellpublishing.com/isth2007/abstract.asp?id=65122>

Eriksson BI, Dahl OE, Büller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. *J Thromb Haemost* 2005;3:103-11.

Eriksson BI, Dahl OE, Ahnfelt L, et al. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. *J Thromb Haemost* 2004;2:1573-80.

Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest* 2004;126(3 Suppl):338S-400S.

American Academy of Orthopaedic Surgeons. American Academy of Orthopaedic Surgeons clinical guideline on prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty. 2007.

[http://www.aaos.org/Research/guidelines/PE\\_guideline.pdf](http://www.aaos.org/Research/guidelines/PE_guideline.pdf)

National Institute for Health and Clinical Excellence. Venous thromboembolism. April 2007.

<http://www.nice.org.uk/guidance/CG/published/CG46>

Ieko M. Drug evaluation: dabigatran etexilate, a thrombin inhibitor for the prevention of venous thromboembolism and stroke. *Curr Opin Investig Drugs* 2007;8:758-68.

Palacioz K. Ximelagatran (Exanta) and liver toxicity. *Pharmacist's Letter* 2004;20(201106).